Literature DB >> 35879479

Impact of pharmacological treatment of gestational diabetes on the mode of delivery and birth weight: a nationwide population-based study on a subset of singleton pregnant Portuguese women.

Diogo Ramalho1, Sara Correia2, Rodrigo Realista3, Gustavo Rocha2, Helena Alves2, Lúcia Almeida2, Eva Ferreira4, Sara Monteiro2, Maria João Oliveira2, Maria Céu Almeida5,6.   

Abstract

AIMS: To access the impact of increasing use of metformin on cesarean section and large for gestational age rates, when compared to insulin.
METHODS: A retrospective observational study was developed using data from the Portuguese National Registry, between 2011 and 2019, of 5038 Portuguese women with single pregnancies and gestational diabetes treated with metformin and/or insulin. Three groups were defined according to the therapeutic regimen adopted: g1-insulin in monotherapy (n = 3027[60.1%]); g2-metformin in monotherapy (n = 1366[27.1%]); g3-metformin and insulin (n = 645[12.8%]). Multivariate analysis was adjusted for statistically significant covariates.
RESULTS: The cesarean section rate in g1 was similar to g2 (g1:36.9% vs. g2:37%, p = 0.982), although g3 was associated with cesarean delivery (g3:43.6% vs. g1:36.9%, p = 0.005; g3:43.6% vs. g1:37.0%, p = 0.002), with no differences reported in the multivariate analysis adjusted for year of delivery and pregestational body mass index. A delivery of a large for gestational age newborn was less frequently observed in g2 than in g1 (g2:4.1% vs. g1:5.4%, p = 0.044) and in g3 (g2:4.1% vs. g3:9.1%, p < 0.001), and in g1, when compared to g3 (g1:5.4% vs. g3:9.1%, p < 0.001). In the multivariate analysis, g2 showed lower odds of delivering a large for gestational age newborn, compared to g1 (β = -0.511, OR = 0.596, CI95% = 0.428-0.832, p < 0.001).
CONCLUSIONS: The use of metformin was not associated with higher cesarean section rates, compared to insulin. Instead, it was suggested a protective role of metformin on large gestational age rates. The concomitant use of dual therapy suggests more complex pregnancies, requiring closer surveillance that mitigate serious perinatal and obstetrical outcomes.
© 2022. Springer-Verlag Italia S.r.l., part of Springer Nature.

Entities:  

Keywords:  Birth weight; Cesarean section; Diabetes; Drug therapy; Gestational; Insulin; Metformin

Mesh:

Substances:

Year:  2022        PMID: 35879479     DOI: 10.1007/s00592-022-01931-x

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.087


  13 in total

1.  Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes.

Authors:  Trecia A Wouldes; Malcolm Battin; Suzette Coat; Elaine C Rush; William M Hague; Janet A Rowan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2016-02-24       Impact factor: 5.747

2.  Metformin versus insulin use for treatment of gestational diabetes and delivery by caesarean section: A nationwide Swedish cohort study.

Authors:  Laura Pazzagli; Lamya Abdi; Helle Kieler; Carolyn E Cesta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2020-09-24       Impact factor: 2.435

Review 3.  Updates in Gestational Diabetes Prevalence, Treatment, and Health Policy.

Authors:  Laura T Dickens; Celeste C Thomas
Journal:  Curr Diab Rep       Date:  2019-05-09       Impact factor: 4.810

4.  Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.

Authors:  H Ijäs; M Vääräsmäki; L Morin-Papunen; R Keravuo; T Ebeling; T Saarela; T Raudaskoski
Journal:  BJOG       Date:  2010-11-18       Impact factor: 6.531

5.  A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months.

Authors:  H Ijäs; M Vääräsmäki; T Saarela; R Keravuo; T Raudaskoski
Journal:  BJOG       Date:  2014-07-16       Impact factor: 6.531

6.  Maternal and neonatal outcomes in pregnancies complicated by gestational diabetes. a nation-wide study.

Authors:  Per Glud Ovesen; Dorte Møller Jensen; Peter Damm; Steen Rasmussen; Ulrik Schiøler Kesmodel
Journal:  J Matern Fetal Neonatal Med       Date:  2015-01-08

7.  Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age.

Authors:  Janet A Rowan; Elaine C Rush; Victor Obolonkin; Malcolm Battin; Trecia Wouldes; William M Hague
Journal:  Diabetes Care       Date:  2011-10       Impact factor: 19.112

Review 8.  Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.

Authors:  Montserrat Balsells; Apolonia García-Patterson; Ivan Solà; Marta Roqué; Ignasi Gich; Rosa Corcoy
Journal:  BMJ       Date:  2015-01-21

Review 9.  A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants.

Authors:  Tanis R Fenton; Jae H Kim
Journal:  BMC Pediatr       Date:  2013-04-20       Impact factor: 2.125

10.  Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis.

Authors:  Jane L Tarry-Adkins; Catherine E Aiken; Susan E Ozanne
Journal:  PLoS Med       Date:  2019-08-06       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.